

Company Number: 173088

Cosgrove's Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 March 2025

Cosgrove's Pharmacy Limited

CONTENTS

	Page
Director and Other Information	3
Director's Responsibilities Statement	4
Balance Sheet	5
Reconciliation of Shareholders' Funds	6
Notes to the Financial Statements	7 - 11

Cosgrove's Pharmacy Limited
DIRECTOR AND OTHER INFORMATION

Director	Helen Cosgrove
Company Secretary	James Cosgrove
Company Number	173088
Registered Office and Business Address	Edward Street Newbridge Co. Kildare
Accountants	Clinton Higgins Chartered Accountants Trident House Dublin Road Naas Co. Kildare
Bankers	Bank of Ireland Newbridge Co. Kildare
Solicitors	Coughlan White & Partners Solicitors Moorefield Road Newbridge Co. Kildare

Cosgrove's Pharmacy Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 31 March 2025

The director made the following statement in respect of the unaudited financial statements:

"General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Director's declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Reconciliation of Shareholders' Funds and the related notes:

The director approves these financial statements and confirms that they is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that they has made available to Clinton Higgins, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The director confirms that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 March 2025."

Signed on behalf of the board

Helen Cosgrove
Director

16 February 2026

Cosgrove's Pharmacy Limited

BALANCE SHEET

as at 31 March 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	8	7,675	9,034
Investments	9	73,791	73,791
Fixed Assets		81,466	82,825
Current Assets			
Stocks	10	40,953	52,697
Debtors	11	147,447	133,258
Cash and cash equivalents		24,552	15,414
		212,952	201,369
Creditors: amounts falling due within one year	12	(200,455)	(200,929)
Net Current Assets		12,497	440
Total Assets less Current Liabilities		93,963	83,265
Capital and Reserves			
Called up share capital presented as equity		127	127
Retained earnings		93,836	83,138
Shareholders' Funds		93,963	83,265

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Cosgrove's Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 16 February 2026 and signed on its behalf by:

Helen Cosgrove
Director

Cosgrove's Pharmacy Limited
RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 31 March 2025

	Called up share capital €	Retained earnings €	Total €
At 1 April 2023	127	103,094	103,221
Loss for the financial year	-	(19,956)	(19,956)
At 31 March 2024	127	83,138	83,265
Profit for the financial year	-	10,698	10,698
At 31 March 2025	127	93,836	93,963

Cosgrove's Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

1. General Information

Cosgrove's Pharmacy Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 173088. The registered office of the company is Edward Street, Newbridge, Co. Kildare which is also the principal place of business of the company. The principal activity of the company is the operation of a general chemist and pharmacy business. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Goodwill

Purchased goodwill arising on the acquisition of a business represents the excess of the acquisition cost over the fair value of the identifiable net assets including other intangible fixed assets when they were acquired. Purchased goodwill is capitalised in the Balance Sheet and amortised on a straight line basis over its economic useful life of 5 years, which is estimated to be the period during which benefits are expected to arise. On disposal of a business any goodwill not yet amortised is included in determining the profit or loss on sale of the business. Goodwill it is now fully depreciated.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Plant and machinery	- 15% Straight line
Fixtures, fittings and equipment	- 15% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Profit and Loss Account in the year in which it is receivable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Cosgrove's Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Going concern

The director has a reasonable expectation that the company has and will have adequate resources to continue in operational existence for the foreseeable future. For this reason, the director continues to adopt the going concern basis in preparing the financial statements.

4. Operating profit/(loss)	2025	2024
	€	€
Operating profit/(loss) is stated after charging:		
Depreciation of tangible assets	1,359	1,449
	<u> </u>	<u> </u>
5. Interest payable and similar expenses	2025	2024
	€	€
Interest	7,783	7,965
	<u> </u>	<u> </u>

6. Employees

The average monthly number of employees, including director, during the financial year was 7, (2024 - 10).

Cosgrove's Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 March 2025

7. Intangible assets

	Goodwill	Total
	€	€
Cost		
At 1 April 2024	279,342	279,342
At 31 March 2025	279,342	279,342
Provision for diminution in value		
At 31 March 2025	279,342	279,342
Net book value		
At 31 March 2025	-	-

8. Tangible assets

	Plant and machinery	Fixtures, fittings and equipment	Total
	€	€	€
Cost			
At 1 April 2024	88,077	236,679	324,756
At 31 March 2025	88,077	236,679	324,756
Depreciation			
At 1 April 2024	79,048	236,674	315,722
Charge for the financial year	305	1,054	1,359
At 31 March 2025	79,353	237,728	317,081
Net book value			
At 31 March 2025	8,724	(1,049)	7,675
At 31 March 2024	9,029	5	9,034

9. Investments

	Listed investments	Other unlisted investments	Total
	€	€	€
Investments			
Cost			
At 31 March 2025	37,838	160,001	197,839
Provision for diminution in value:			
At 31 March 2025	33,492	90,556	124,048
Net book value			
At 31 March 2025	4,346	69,445	73,791
At 31 March 2024	4,346	69,445	73,791

Cosgrove's Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

10. Stocks	2025	2024
	€	€
Finished goods and goods for resale	40,953	52,697

The replacement cost of stock did not differ significantly from the figures shown.

11. Debtors	2025	2024
	€	€
Trade debtors	76,319	68,122
Taxation	4,450	6,076
Prepayments	66,678	59,060
	147,447	133,258

The fair values of trade debtors and other debtors approximate to their carrying amounts. Debtors are reviewed on an ongoing basis to assess whether any provisions against doubtful debts are required. Taxation is repayable in accordance with statutory provisions.

12. Creditors	2025	2024
Amounts falling due within one year	€	€
Amounts owed to credit institutions	123,967	125,657
Net obligations under finance leases and hire purchase contracts	-	2,115
Trade creditors	72,681	50,508
Taxation	4,956	5,514
Director's current account (Note 15)	828	14,117
Other creditors	(1,977)	-
Accruals	-	3,018
	200,455	200,929

Trade creditors and accruals are payable in accordance with standard commercial credit terms. Taxation is payable in accordance with statutory provisions. Amounts owed to director have no fixed repayment schedule, are interest free and repayable on demand.

13. Profit and loss account	2025	2024
	€	€
At 1 April 2024	83,138	103,094
Profit/(loss) for the financial year	10,698	(19,956)
At 31 March 2025	93,836	83,138

14. Capital commitments

The company had no material capital commitments at the financial year-ended 31 March 2025.

15. Director's remuneration and transactions	2025	2024
	€	€
Remuneration	131,950	121,270
Pension contributions	4,850	5,636
	136,800	126,906

Cosgrove's Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 March 2025

16. Controlling interest

Maeve Cosgrove owns 51% of the shares and is therefore regarded as the ultimate controlling party.

17. Post-Balance Sheet Events

There were no significant events after the balance sheet date.

18. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 16 February 2026.